02:16 PM EDT, 10/24/2024 (MT Newswires) -- Inozyme Pharma ( INZY ) said Thursday results of a phase 1 trial of INZ-701 in patients with end-stage kidney disease undergoing hemodialysis were encouraging.

The interim trial data showed the drug candidate "significantly" raised plasma pyrophosphate, or PPi, levels in patients and was well-tolerated, the company said. It said low PPi levels are associated with a rare and serious skin condition called calciphylaxis, a life-threatening complication of end-stage kidney disease.

Inozyme said the data, which will be presented at the ongoing Kidney Week 2024 event of the American Society of Nephrology in San Diego, underpins a "registrational trial" for INZ-701 in calciphylaxis, which it plans for next year, subject to regulatory alignment and sufficient funding.

The company's shares were up more than 1% in recent trading.

Price: 4.97, Change: +0.07, Percent Change: +1.43